This systematic review offers encouraging results that place the SGLT2-i class at the top of the therapeutic arsenal for patients diagnosed with T2DM and NAFLD/NASH. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.